A decade of discovery and development of new anti-malarial medicines has led to a
renewed focus on malaria elimination and eradication. Changes in the way new anti …

Artemisinin-based combination therapies (ACTs) have become the mainstay for malaria
treatment in almost all malaria endemic settings. Artemisinin derivatives are highly potent …

The resistance of malaria parasites to existing drugs carries on growing and progressively
limiting our ability to manage this severe disease and finally lead to a massive global health …

Abstract Background The World Health Organization recommends regularly assessing the
efficacy of artemisinin-based combination therapy (ACT), which is a critical tool in the fight …

Background Artemether–lumefantrine and artesunate–amodiaquine are used as first-line
artemisinin-based combination therapies (ACTs) in west Africa. Pyronaridine–artesunate …

Malaria disproportionately affects children younger than 5 years. Falciparum malaria is
responsible for more than 200 000 child deaths per year in Africa and vivax malaria is well …

Background Artemisinin-based combination therapy (ACT) was deployed in 2005 as an
alternative to chloroquine and is considered the most efficacious treatment currently …

Pyronaridine (PYR) is an erythrocytic schizonticide with a potent antimalarial activity against
multidrug‐resistant Plasmodium. The drug is used in combination with artesunate for the …

Pyronaridine-artesunate was recently strongly recommended in the 2022 update of the
WHO Guidelines for the Treatment of Malaria, becoming the newest artemisinin-based …

Introduction: Plasmodium falciparum, the deadly agent of malaria, is notorious for its
capacity to develop drug resistance. Treatment failures of artemisinin therapy regimens …